2007 Press Releases Communiqués de presse

December 10, 2007 10 December, 2007

Successful Completion of Preclinical Sertolin Study: Regulatory Guidance Sought for Clinical Approval

September 24, 2007 24 September, 2007

FDA Consultant to Help Guide Sernova Through Regulatory Approval Process

September 10, 2007 10 September, 2007

Sertoli Cells Successfully Engineered to Secrete Insulin and are Effective in Preclinical Models of Diabetes

July 30, 2007 30 July, 2007

Sernova Files Worldwide Patent Application for Innovative Component of Diabetes

May 9, 2007 9 May, 2007

Sernova Raises $2.4 Million to Advance Sertolin to Clinical Trails

May 3, 2007 3 May, 2007

Sernova Directors and Management Established for 2007/2008 -- Dr. George Adams Named Chair; Justin Leushner Becomes CEO

April 16, 2007 16 April, 2007

Journal of Clinical Immunology: Sertoli Cells Could Replace Immunosuppressive Drugs in Humans

April 2, 2007 2 April, 2007

Sernova Corp. Information To Be Available Through S&P Market Access Program

February 5, 2007 5 February, 2007

Pre-Clinical Milestones for Sertolin Cell Replacement Technology: Insulin-Producing Cells Survive and Function without Anti-Rejection Drugs

January 8, 2007 8 January, 2007

Award Winning Harvard Diabetes Specialist Appointed to Help Advance Sernova's Sertolin Diabetes Therapy to Clinical Trials

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 10, 2007 10 December, 2007

Successful Completion of Preclinical Sertolin Study: Regulatory Guidance Sought for Clinical Approval


Kelowna, B.C. - Sernova Corp. ("Sernova") is pleased to announce completion of a comprehensive preclinical efficacy animal study for its lead product Sertolin, which is a combination of porcine Sertoli cells and pancreatic islet cells for the treatment of diabetes. The benefits of Sertolin are the ability to replace insulin producing cells that have been destroyed in a diabetic patient without the need for anti-rejection drugs, and using the unlimited supply of porcine derived cells. After conferring with its Scientific Advisory Board and regulatory consultants, Sernova believes it has completed the recommended Sertolin preclinical studies and is seeking guidance from health regulators in Canada and the US to determine what, if any, additional data is required prior to applying for approval to begin clinical trials.

"After a lot of hard work and some ground breaking experiments by our research team, we have established positive data using Sertolin to treat diabetes in the recommended animal model," stated Dr. David White, Sernova's principal researcher. "We will now approach the various health regulators and move forward based on their guidance."

Summary of Results to Date: Four Key Outcomes Islet and Sertoli Cell Isolation and Survival - A reliable process to isolate insulinproducing pig islet cells and Sertoli cells has been established by the Company. In 100% of implants into animals, the islets and Sertoli cells have been shown to survive for extended periods with no detectable side effects to the animal and without the use of any anti-rejection drugs. Porcine Insulin Production - In addition to islet survival, porcine insulin is being produced in the test animals, and the amount of insulin released increases when blood sugar levels are elevated by a fasting glucose challenge test. Animal Health - In the diabetic Lewis rats transplanted with Sertolin, the overall health of the animals was maintained compared to diabetic Lewis rats that did not receive Sertolin. This was demonstrated by healthy weight maintenance in the transplanted rats compared to significant diabetes-related weight loss and early death in the untreated animals. Animal Model Validation - In developing a therapeutic for human use, the Company used the Lewis rat animal model as discussed with the USFDA. While animal models are often imperfect representations of human response, they are a necessity for clinical trial approval. Sernova has demonstrated that Sertolin offers a drug free approach to insulin cell replacement for diabetics, and can lower blood sugar levels in the Lewis rat model; however normalization has not been achieved. This is expected, as further investigations have demonstrated that Lewis rats are significantly non-responsive to porcine insulin. Using pharmaceutical grade porcine insulin, regularly used in humans, Sernova researchers demonstrated that even a 40 fold increase in physiological dosage did not normalize blood sugar levels in the Lewis rats, despite the survival of the insulin producing cells. These studies demonstrate the drawbacks of animal models for diabetes and provide data for future human studies. Because porcine insulin is known to be compatible with humans, and was the primary source of injected insulin for most of the last century, this issue is not expected to be a concern in human applications. President & CEO Justin Leushner stated that "The Company has completed preclinical studies agreed to by the USFDA and is preparing for the next phase of clinical development with its Sertolin product. In addition, we have shown the long-term survival and effectiveness of Sertoli cells to protect transplanted cells from immune rejection without harmful anti-rejection drugs. This approach may represent a breakthrough in the treatment of diabetes, and could be applied to other cell-based therapies in the future."

Charles Allard Resigns

Sernova also wishes to announce that Charles Allard has resigned from its Board of Directors. Mr. Allard informed the Board that while he remains very interested in Sernova's research, his other business commitments have become too time consuming to give adequate attention to the Company.

The Board does not have any immediate plans to replace Mr. Allard with a new Director.

Commented Sernova Chair George Adams, "Chuck brought with him a wealth of business experience and an intense desire to see real improvement in diabetes treatment. We are very sorry to see him go, but respect his decision to do so and wish him all the best."

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: TEL: (888) 318-7062 Phil Morehouse FAX: (250) 868-8493 Sernova Corp. info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 24, 2007 24 September, 2007

FDA Consultant to Help Guide Sernova Through Regulatory Approval Process


Kelowna, British Columbia -- September 24, 2007 - Sernova Corp. (TSX-V: SVA) today announced that it has retained the services of Arent Fox LLP to represent Sernova in matters before the US Food and Drug Administration (FDA). Arent Fox partner, James Ravitz, has successfully guided novel cellular therapy products through the FDA regulatory process.

"Cellular therapy is an emerging therapeutic approach and it is important we provide the FDA with the correct preclinical data in our Investigational New Drug application to allow testing of our diabetes therapy, Sertolin, in humans." said Sernova CEO Justin Leushner. "Mr. Ravitz's and Arent Fox's previous experience and success in this specialized area clearly make them the best choice for strategically advising us toward our regulatory goals."

About Arent Fox

Arent Fox LLP, with offices in Washington, DC, New York and Los Angeles, is a recognized leader in areas including intellectual property, health care, life sciences, and complex litigation. With over 300 lawyers nationwide, Arent Fox has extensive experience in corporate securities, real estate, financial restructuring, bankruptcy, government relations, labor and employment, finance, tax, corporate compliance, and the global business market. The firm represents Fortune 500 companies, government agencies, trade associations, foreign governments, and other entities.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin(tm) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 10, 2007 10 September, 2007

Sertoli Cells Successfully Engineered to Secrete Insulin and are Effective in Preclinical Models of Diabetes


Kelowna, British Columbia - September 10, 2007 - Sernova Corp. (TSX-V: SVA) would like to congratulate Dr. Jannette Dufour and Ms. Katie Halley who have reversed diabetes in an animal model by genetically engineering Sertoli cells to secrete insulin. Sernova owns the exclusive patent rights for the therapeutic use of Sertoli cells to treat diseases including diabetes. These results support the concept that Sertoli cells could be an "implanted drug factory" for numerous disease applications.

"Dr. Dufour's research is an important finding for the future treatment of diabetes, and other diseases caused by a deficiency in a hormone, protein, or enzyme, because it appears Sertoli cells can be made to secrete any number of therapeutic factors," commented Dr. David White, Sernova's Principal Researcher. "We know from our studies that the immunoprotective properties of Sertoli cells make them ideal candidates for a drug delivery system that can be transplanted without the need for anti- rejection drugs."

Stated Justin Leushner, Sernova's CEO, "These findings demonstrate the versatility of our Sertoli technology which has been protected in Sernova's many worldwide patents and patent applications. Our core Sertolin�¢ program of using Sertoli cells in combination with islet cells as a treatment for diabetes is continuing. Concurrently we will explore the possibilities for developing therapeutic applications based on these exciting results."

Dr. Dufour, who is a member of Sernova's Scientific Advisory Board and is on faculty at Texas Tech University Health Sciences Center, will present the study at the joint conference of the Cell Transplant Society, International Pancreas and Islet Transplant Association, and International Xenotransplantation Association being held in Minneapolis on September 15 - 20, 2007.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin� cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 30, 2007 30 July, 2007

Sernova Files Worldwide Patent Application for Innovative Component of Diabetes


Kelowna, British Columbia -- July 30, 2007 - Sernova Corp. (TSX-V: SVA), a company focused on a novel treatment for insulin-dependent diabetes using its Sertolin cell technology, is pleased to announce it has filed a patent application for the therapeutic use of adult Sertoli cells. Compared to the standard juvenile cells, adult Sertoli cells have enhanced protective properties that are particularly effective at protecting co- transplanted cells from being destroyed by the body's immune system.

Sernova has demonstrated that adult Sertoli cells protect insulin-producing islet cells in animal xenotransplants (pig cells implanted into rats), whereas xenotransplants using only islets are destroyed by the immune system within 7 days. Using the Company's Sertolin technology containing adult Sertoli cells, implants have been shown to produce insulin and decrease insulin-dependence for up to 100 days in diabetic rats.

The patent application complements Sernova's existing portfolio of over 20 patents and several additional patent applications related to the use of Sertoli cells for therapeutic purposes and gene therapy. The application was filed under the Patent Cooperation Treaty (PCT) and extends Sernova's previously filed U.S. provisional application to most countries, including all important industrialized markets.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact: TEL: (888) 318-7062 Phil Morehouse FAX: (250) 868-8493 Sernova Corp. info@sernova.com www.sernova.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 09, 2007 9 May, 2007

Sernova Raises $2.4 Million to Advance Sertolin to Clinical Trails


-Completes Acquisition of All Rights to Sertoli Technology-

Kelowna, British Columbia - May 9, 2007 - Sernova Corp. (TSX-V: SVA), a company focused on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology, announced that it has raised $2.4 million through the exercise of all outstanding warrants. The funds will be used to continue the Company's development of Sertolin, Sernova's cellular therapy for diabetes.

"The warrant exercise was an ideal way for us to raise capital for the Sertolin project without diluting our current share structure," said CEO Justin Leushner. "The company appreciates the continued support by its shareholders."

Under the terms of the warrant agreement, the Company had a right to trigger the exercise of the warrants when the 10 day average of the closing price of the Company's shares was equal to or above $1.00 per share. With this condition met, Sernova notified warrant holders that they had until May 7, 2007 to complete the exercise of the warrants. All 4,036,375 outstanding warrants were exercised at $0.60 per share.

Sernova also announced that it now has sole control of the Sertolin technology. With the proceeds from the exercise of the warrants, Sernova has met its financing commitments for the Sertolin technology and will complete its obligations under the original financing agreement to issue an additional 2,315,000 escrow shares. (See the Company's news release dated May 25, 2006.) Sernova has also made a cash payment of $1,142,312 to Sertoli Technologies Inc. for the exclusive license to the Sertoli cells patents. There are no further payments required under the license agreement, except for a continuing obligation to pay a small royalty on future commercial sales of products based upon the use of Sertoli cells.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin are estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

For further information contact:

TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Sernova Corp.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 03, 2007 3 May, 2007

Sernova Directors and Management Established for 2007/2008 -- Dr. George Adams Named Chair; Justin Leushner Becomes CEO


Sernova Corp. (TSX-V: SVA) is pleased to announce that Sernova Director Dr. George Adams has been appointed Chair of the Board of Directors, effective immediately. Dr. Adams, who is also CEO and a director of Amorfix Life Sciences Ltd. (TSX-V: AMF), replaces long time Chairman Dr. William Cochrane, who asked to step down from the position. Dr. Cochrane will continue to serve as a director and member of board committees.

The Company wishes to thank Dr. Cochrane for his steady and experienced guidance during his 6 year tenure as Chairman of the Board, and expresses its appreciation that Sernova will continue to benefit from his wealth of wisdom and knowledge.

At the same meeting Devinder Randhawa, Chairman and CEO of Strathmore Mineral Corp. (TSX-V: STM) and Pacific Asia China Energy Inc. (TSX-V: PCE) was appointed as Vice-Chair and Justin Leushner assumed the position of President and CEO. Patrick Groening will remain as Corporate Secretary and CFO, and Phil Morehouse as Executive Vice-President.

On April 19, 2007 the company held its annual general meeting and elected 6 directors to the Board: Dr. George Adams, Charles Allard, Dr. William Cochrane, Justin Leushner, Devinder Randhawa and Dr. Eldon Smith.

About George Adams

Currently CEO and director of Amorfix Life Sciences, Dr. Adams has an extensive history of combining science and entrepreneurial ventures. In the late 1980's he left his position as a Senior Scientist with The Canadian Red Cross Blood Transfusion Service to found the University of Ottawa's Artificial Heart Development Program which is now World Heart. In the early 1990's, he started his own company Hemo-Stat in alliance with DuPont Canada to develop diagnostic products. In 1994 he became the controlling shareholder and President of Corvita Canada and financed its research program until the company was purchased by Pfizer in 1996 and later re-sold to Boston Scientific in 1998.

He has also previously served as CEO of the University of Toronto Innovations Foundation where he founded and obtain financing for several companies based upon breakthrough discoveries. He obtained his Ph.D. in Medical Sciences from McMaster University after completing his B.A.Sc. and M.A.Sc. in Mechanical Engineering at the University of Waterloo.

About Devinder Randhawa Mr. Randhawa founded and is currently the President of RD Capital Inc., a privately held consulting firm providing venture capital and corporate finance services to emerging companies in Canada and the US. Mr. Randhawa also founded Strathmore Minerals Corp. in 1996 and Pacific Asia China Energy Inc. in 2005 and is currently Chairman and CEO of both companies. Mr. Randhawa was formerly the President of Lariat Capital Inc. which merged with Medicure Inc. in November 1999, and was the founder and former President and CEO of Royal County Minerals Corp. which was acquired by Canadian Gold Hunter in 2003. He received his Masters in Business Administration from the University of British Columbia in 1985.

About Justin Leushner Mr. Leushner has had an extensive and diverse business career in the life sciences and biotechnology industries. In addition to developing a clinical islet transplant program for the London Health Sciences Centre, he co- founded Sertonex Inc. with Dr. David White, now Sernova's primary researcher on the diabetes project. Mr. Leushner was also responsible for developing a national molecular diagnostics program for MDS Inc., Canada's largest life science's company, and served as a business analyst and portfolio advisor to the Canadian Medical Discoveries Fund. An MBA graduate of the University of Western Ontario's Ivey School of Business, Mr. Leushner also holds a B.Sc. in Cell Physiology/Genetics from the University of British Columbia and numerous technical designations in Forensic Science and Molecular Biology.

About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President and CEO

For further information contact:

TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Sernova Corp.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 16, 2007 16 April, 2007

Journal of Clinical Immunology: Sertoli Cells Could Replace Immunosuppressive Drugs in Humans


Sernova Corp. (TSX-V: SVA) is pleased to announce the peer reviewed, scientific publication of a Sertoli cell study on humans, co-authored by Dr. David White, Sernova's principal researcher and Novartis/Stiller Chair of Xenotransplantation at the University of Western Ontario. The study is published in the March 2007 issue of The Journal of Clinical Immunology.

The study reviewed a 6-year follow-up of the immune responses in human diabetic patients who received transplants of porcine Sertoli cells and insulin producing islets without immunosuppressive drugs. The results confirmed that the Sertoli cells reduce the immune responses and allow the survival of the transplanted islets. This is the first human study demonstrating the potential of porcine Sertoli cells for replacing anti-rejection drugs in transplants. Sernova Corp owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells, which are a key component of Sertolin, the Company's experimental diabetes treatment.

David White noted that "Sernova's experimental animal models have confirmed what we see in the clinical results: Sertoli cells provide a means to co-transplant other cell types and provide immune protection without the need for immunosuppressive drugs. Our research has found a way to improve the immunoprotective properties of the Sertoli cells, but this study's data is still useful to us because it demonstrates clinical benefit in humans and that should enhance our efforts to prove the technology and gain regulatory approval for its use in humans. "

Justin Leushner, President of Sernova stated "It is encouraging to see evidence that the Sertoli cells do indeed provide immune protection in humans. Having a cell type that is immunoprivileged and can therefore be implanted without the need for anti-rejection drugs provides us with a pipe-line for a host of other therapeutic applications. Our current focus is the co- transplantation of insulin producing cells with our Sertoli cell technology for treating insulin dependent diabetes. However this does not preclude us from using Sertoli cells with other cell types or even using Sertoli cells as a vehicle for gene therapy."

About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD "Justin Leushner" Justin Leushner, President

For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

Phil Morehouse Sernova Corp.

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 02, 2007 2 April, 2007

Sernova Corp. Information To Be Available Through S&P Market Access Program


Sernova Corp. (TSX-V: SVA) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Sernova will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under the Blue Sky Laws.

"Participation in S & P's Market Access Program is an important step in our efforts to broaden the audience for Sernova and the work it is doing," stated Sernova CEO Dev Randhawa, "We want to ensure information on the Company is readily accessible to brokers and investors in the United States."

About Sernova

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: TEL: (888) 318-7062 Phil Morehouse FAX: (250) 868-8493 Sernova Corp. info@sernovacorp.com www.sernovacorp.com

Standard & Poor's Customer Contact: Maria Cruz 212 438-3671 maria_cruz@sandp.com

Standard and Poor's Media Relations Contact: Michael Privitera 212 438-6679 michael_privitera@sandp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 05, 2007 5 February, 2007

Pre-Clinical Milestones for Sertolin Cell Replacement Technology: Insulin-Producing Cells Survive and Function without Anti-Rejection Drugs


Kelowna, British Columbia - Sernova Corp. (TSX-V: SVA), is pleased to announce its preliminary, preclinical animal studies have demonstrated long term survival and functioning of Sertolin, the Company's patented insulin producing cellular replacement therapy. The findings will be presented at the upcoming Canadian Society of Transplantation Annual General Meeting March 16, 2007.

These critical milestones, which are required for regulatory filings, were achieved in two separate studies. In one study, non-diabetic rats showed the predicted, extended survival of functioning, insulin-secreting cells several months after transplant. Importantly, the data shows the insulin producing cells are accepted by the recipient's immune system without using toxic anti-rejection drugs.

In the other preliminary study using diabetic animals treated with Sertolin, the insulin producing cells demonstrated function for several months. When the insulin producing cells and Sertoli cells were later removed, the animals became diabetic again.

"Having the ability to implant foreign cells into a patient without having to use immunosuppressive drugs to prevent rejection is extremely important for the treatment of a whole host of diseases," stated Dr. David White, principal researcher for Sernova. "The ability to implant cells from a different species without harmful immunological side effects could make cellular replacement a routine procedure."

The next stage in the development of Sertolin is to reverse diabetes in a larger number of test animals, improve the efficacy and prove statistical significance. Also included in current pre-clinical studies is the dosage study and optimization of transplant site. Sernova anticipates having these studies completed by the summer of this year, leading to an Investigational New Drug ("IND") filing later in the year.

"We are well on our way to achieving our goal of treating diabetes through this cellular replacement technology," commented Justin Leushner, President of Sernova Corp. "Since we set out to develop this technology we have remained focused on generating data that moves us closer to having this therapy available to the patients that need it. When working with an animal model it takes time to optimize the model itself and because we are dealing with a technology that requires proof of long term efficacy, we have to wait several months for each of these experiments to run its course. Knowing we have clearly defined milestones and a model that works we can now expedite all the necessary experiments required for our IND filing. With that said I am very encouraged by our results to date and excited about the future of this technology."

Sernova's research is focused on compiling pre- clinical data to support an IND application to the United States Food and Drug Administration for Sertolin Diabetes Therapy. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

About Sernova

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President

For further information contact: TEL: (888) 318-7062 Phil Morehouse FAX: (250) 868-8493 Sernova Corp. info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 08, 2007 8 January, 2007

Award Winning Harvard Diabetes Specialist Appointed to Help Advance Sernova's Sertolin Diabetes Therapy to Clinical Trials


Kelowna, B.C. - Sernova Corp. ("Sernova") is pleased to announce that Dr. George King, Senior Vice President and Director of Research at Harvard Medical School's Joslin Diabetes Center, has accepted an appointment to Sernova's Scientific Advisory Board.

One of the world's foremost diabetolgists, Dr. King has an extensive and successful history of conducting research into the causes, complications and treatment options of diabetes. Dr. David White, principal researcher for Sernova states, "With such an intricate understanding of the biology of diabetes, Dr. King will be an excellent advisor for our preclinical studies and be of great assistance during our application process to the FDA and other health regulators."

Dr. King commented, "This is a promising cellular therapy for treating diabetes so I look forward to assisting Sernova to advance the technology. Being an emerging technology, xenotransplantation needs to proceed with meticulous attention to accepted medical and research practises and I believe Sernova will follow these protocols closely."

About Dr. King

Dr. King received his medical degree from Duke University Medical School, completed residency training at the University of Washington Affiliated Hospitals in Seattle, and then completed research training at the National Institutes of Health in Bethesda Maryland. He has been at the Joslin Clinic and Harvard Medical School since 1981. He is currently the Director of Research and Head of the Section on Vascular Cell Biology at Joslin, and a Professor of Medicine at Harvard Medical School.

Dr. King has received numerous awards including the Donald Silver Excellence in Research Award from the Juvenile Diabetes Foundation, the Cogan Award from the Association for Research in Vision and Ophthalmology, the Stadie Memorial Award and Lectureship from the Philadelphia Affiliate of the American Diabetes Association, the Alcon Award for Vision Research, and the Annual Award for Excellence in Research from the Japan Society of Diabetic Complications.

About Sernova

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD "Justin Leushner" -------------------------- Justin Leushner, President

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.